# Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

> **NCT06500247** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 43 (estimated)

## Conditions studied

- The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Dalpicilib
- **DRUG:** Abiraterone Acetate (II)
- **DRUG:** Androgen Deprivation Therapy
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06500247
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500247, "Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06500247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*